$Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis$

Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis

BackgroundMultiple myeloma (MM) is a hematological malignancy with limited treatment options for patients with relapsed/refractory MM (RRMM). Teclistamab, a B-cell maturation antigen (BCMA) × CD3 bispecific antibody, has shown promising results in clinical trials and real-world studies.MethodsPubMed...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wenze Li, Defeng Zhao, Yu Jiao, Weilin Dong, Ziyi Wang, Xiaojing Yan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-04-01
Series:	Frontiers in Immunology
Subjects:	teclistamab relapsed or refractory multiple myeloma meta-analysis bispecific antibodies systematic review
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1565407/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Injection site reaction to teclistamab in a patient with multiple myeloma
by: Isabel C. Yoon, BS, et al.
Published: (2025-02-01)

Case Report: Reactive T-cell large granular lymphocytes in the bone marrow of a patient with relapsed/refractory multiple myeloma receiving teclistamab
by: Erin A. Dean, et al.
Published: (2025-08-01)

A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma
by: Alfred L. Garfall, et al.
Published: (2025-07-01)

Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
by: Asis Shrestha, et al.
Published: (2025-04-01)

Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma
by: A P Dubey, et al.
Published: (2020-01-01)

Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group
by: Jiri Minarik, et al.
Published: (2025-04-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti‐CD38 Monoclonal Antibodies: A Systematic Review
by: Chia Jie Tan, et al.
Published: (2025-03-01)

Treatment refractoriness and response rates in patients with relapsed/refractory multiple myeloma: a retrospective analysis of real-world data
by: Ning Lyu, et al.
Published: (2025-01-01)

Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature review
by: Francesca Gay, et al.
Published: (2025-03-01)

Isatuximab in the treatment of refractory and relapsed multiple myeloma: literature review and case report
by: Yu. E. Ryabukhina, et al.
Published: (2023-12-01)

Pomalidomide for the management of relapsed and refractory multiple myeloma: a case report and review of literature
by: S. V. Semochkin
Published: (2015-10-01)

Ciltacabtagene Autoleucel for the Treatment of Relapsed/Refractory Multiple Myeloma: Efficacy, Safety, and Place in Therapy
by: Goel U, et al.
Published: (2025-02-01)

Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)
by: Josip Batinić, et al.
Published: (2024-11-01)

Efficacy of IsaPomDex triplet therapy in double refractory multiple myeloma patients in real clinical practice in Russia
by: M. V. Solovev, et al.
Published: (2024-12-01)

The impact of antibiotic use on outcomes of relapsed/refractory multiple myeloma patients treated with CAR-T therapy
by: Lingling Yin, et al.
Published: (2025-04-01)

Extramedullary Multiple Myeloma: Challenges and Opportunities
by: Matthew Ho, et al.
Published: (2025-03-01)

Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen
by: Andrew Whiteley, et al.
Published: (2025-05-01)

Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
by: Barry Paul, et al.
Published: (2025-06-01)

A case report of relapsed and refractory multiple myeloma with multifocal extramedullary infiltration and pulmonary adenocarcinoma
by: DU Fang, et al.
Published: (2025-01-01)

Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi‐Center, Open‐Label Phase I Trial
by: Ya‐Lan Zhou, et al.
Published: (2025-04-01)

Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myeloma
by: Wenjiao Tang, et al.
Published: (2024-07-01)

Elotuzumab in the treatment of patients with refractory and relapsed multiple myeloma Experience of the Lapino Clinical Hospital Oncohematology Department
by: Yu. E. Ryabukhina, et al.
Published: (2023-12-01)

Treatment pattern among patients with relapsed/refractory multiple myeloma (RRMM) who had received pomalidomide-based regimens in Taiwan
by: Chieh-Lin Jerry Teng, et al.
Published: (2024-12-01)

Comparison of outcomes with elranatamab and real world treatments in the UK for triple class exposed relapsed and refractory multiple myeloma
by: Carmen Tsang, et al.
Published: (2025-07-01)

Haploidentical Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Extramedullary Multiple Myeloma: A Conditioning Regimen Combining Selinexor and Helical Tomotherapy—A Case Report and Literature Review
by: Chen B, et al.
Published: (2025-04-01)

Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study
by: V. G. Potapenko, et al.
Published: (2022-07-01)

Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma
by: Andrée-Anne Pelland, et al.
Published: (2025-04-01)

BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma
by: Yuhan Yan, et al.
Published: (2024-11-01)

Tumor Lysis Syndrome with Venetoclax/Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Case Report
by: Reilly Fankhauser, et al.
Published: (2024-11-01)

CD20×CD3 bispecific antibody achieved significant efficacy in patients with large B-cell lymphoma relapsing after or refractory to CAR-T therapy: a systematic review and meta-analysis
by: Jing Shen, et al.
Published: (2025-08-01)

Efficiency of pomalidomide therapy in patients with multiple myeloma refractory to lenalidomide
by: I. G. Rekhtina, et al.
Published: (2019-04-01)

Application of GPRC5D Targeting Therapy in Relapsed Refractory Multiple Myeloma
by: Sijia Yan, et al.
Published: (2025-03-01)

Risk of infections in bispecific antibody therapy for multiple myeloma: a comprehensive review of literature
by: Fahad Alshammari, et al.
Published: (2025-12-01)

Efficacy of Anti-CD38 Monoclonal Antibodies for Relapsed or Refractory Multiple Myeloma in Stem Cell Transplant-Ineligible Patients Aged over 65 Years: A Propensity Score-Matched Study
by: Satoshi Yamasaki, et al.
Published: (2024-11-01)

Elranatamab in Heavily Pretreated Triple-class Refractory Multiple Myeloma: A Single-center Experience
by: Ant Uzay
Published: (2025-08-01)

BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial
by: Hao Yao, et al.
Published: (2025-05-01)

Visualizing immunotherapy for multiple myeloma worldwide from 2013 to 2023: A bibliometric analysis
by: Jinqiao Li, et al.
Published: (2024-12-01)

Exploring what matters most to patients in relapsed refractory multiple myeloma treatment: a Canadian discrete choice experiment with patients, caregivers and physicians
by: Rebekah Hall, et al.
Published: (2025-07-01)

Treatment of double-refractory multiple myeloma
by: S. V. Semochkin
Published: (2021-09-01)